A detailed history of Morgan Stanley transactions in Coll Plant Biotechnologies LTD stock. As of the latest transaction made, Morgan Stanley holds 1 shares of CLGN stock, worth $4. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1
Previous 1 -0.0%
Holding current value
$4
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$4.97 - $6.64 $596 - $796
-120 Reduced 99.17%
1 $0
Q2 2023

Aug 14, 2023

SELL
$6.6 - $8.23 $330 - $411
-50 Reduced 29.24%
121 $0
Q4 2022

Feb 14, 2023

SELL
$4.71 - $9.5 $9 - $19
-2 Reduced 1.16%
171 $1,000
Q3 2022

Nov 14, 2022

BUY
$6.3 - $9.99 $774 - $1,228
123 Added 246.0%
173 $1,000
Q2 2022

Oct 27, 2022

SELL
$8.0 - $11.19 $1,600 - $2,238
-200 Reduced 80.0%
50 $0
Q2 2022

Aug 15, 2022

SELL
$8.0 - $11.19 $1,600 - $2,238
-200 Reduced 80.0%
50 $0
Q1 2022

Oct 27, 2022

BUY
$8.97 - $16.4 $1,794 - $3,279
200 Added 400.0%
250 $3,000
Q1 2022

May 13, 2022

SELL
$8.97 - $16.4 $4,224 - $7,724
-471 Reduced 65.33%
250 $3,000
Q4 2021

Feb 14, 2022

BUY
$12.0 - $22.48 $8,052 - $15,084
671 Added 1342.0%
721 $12,000
Q3 2021

Nov 15, 2021

BUY
$16.0 - $21.75 $800 - $1,087
50 New
50 $1,000

Others Institutions Holding CLGN

About CollPlant Biotechnologies Ltd


  • Ticker CLGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,086,500
  • Market Cap $46.6M
  • Description
  • CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering tech...
More about CLGN
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.